![Richard Hawkins](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 658 287 $ al 31/08/2026
Mr. Richard J.
Hawkins is a Chairman at Entvantage Diagnostics, Inc., an Independent Director at Savara, Inc., a Chairman at Plus Therapeutics, Inc., a President & Chief Executive Officer at id2, Inc and an Operating Partner at Havencrest Capital Management LLC.
He is on the Board of Directors at Savara, Inc. and Cytori Therapeutics, Inc. Mr. Hawkins was previously employed as a Chairman, President & Chief Executive Officer by NewLink Genetics Corp., a Chairman & Chief Executive Officer by Lumos Pharma, Inc., a Chairman & Chief Executive Officer by Lumos Pharma Sub, Inc., an Independent Director by SciClone Pharmaceuticals, Inc., a Chairman, President & Chief Executive Officer by LabNow, Inc., a Chairman by Sensus Drug Development Corp., a Chairman, President & Chief Executive Officer by Pharmaco, a Board member by Aravas, Inc., a General Partner by Dominion Ventures, Inc., and a Chairman by LoopOne, Inc. He also served on the board at Aravas, Inc., Covance Biotechnology Services, Inc., Diosynth RTP, Inc., Entvantage Diagnostic Associates LLC and Synexus Compass, Inc. He received his undergraduate degree from The Ohio University.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
SAVARA, INC. 0,06 % | 06/04/2026 | 121.326 ( 0,06 % ) | 653 947 $ | 31/08/2026 |
CERENOME, INC. 0,02 % | 01/07/2026 | 1.529 ( 0,02 % ) | 4 312 $ | 31/08/2026 |
| 25/07/2018 | 10 ( -.--% ) | 28 $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| CERENOME, INC. | Presidente | 25/01/2018 |
| SAVARA INC. | Director/Miembro de la Junta | 01/10/2010 |
Havencrest Capital Management LLC
 Havencrest Capital Management LLC Investment ManagersFinance Havencrest Capital invests in lower-middle market companies located in the United States with an EBITDA of USD 3 - 15 million and enterprise value of USD 25 - 250 million. The firm focuses on a broad range of sectors and industries. It participates in add on acquisitions, buyouts, recapitalization and growth stage capital transactions. It acquires controlling and non controlling stakes. | Inversor de Capital Privado | - |
Cytori Therapeutics, Inc.
 Cytori Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treatment and devices for cell therapy | Director/Miembro de la Junta | - |
Entvantage Diagnostics, Inc.
 Entvantage Diagnostics, Inc. Medical SpecialtiesHealth Technology Develops diagnostic test kits | Fundador | 01/01/2014 |
id2, Inc
 id2, Inc Information Technology ServicesTechnology Services Provides custom computer programming services | Director Ejecutivo | 01/01/1992 |
| Empresas | Cargo | Fin |
|---|---|---|
| LUMOS PHARMA, INC. | Director Ejecutivo | 01/12/2024 |
Entvantage Diagnostic Associates LLC
 Entvantage Diagnostic Associates LLC BiotechnologyHealth Technology Operates as biotechnology company | Director/Miembro de la Junta | 12/09/2022 |
| SCICLONE PHARMACEUTICALS, INC. | Director/Miembro de la Junta | 01/12/2017 |
| ░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░ | ░░░░░░░░ ░░░░░░░░░ | ░░░░░░░░░░ |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 21 |
|---|---|
SciClone Pharmaceuticals LLC
 SciClone Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of cancer and infectious diseases | Health Technology |
Sensus Drug Development Corp.
 Sensus Drug Development Corp. Pharmaceuticals: OtherHealth Technology Develops drugs to treat endocrine disorders | Health Technology |
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology Discovers, develops, and commercializes novel immunotherapeutic products for treatment of cancer | Health Technology |
LabNow, Inc.
 LabNow, Inc. Medical SpecialtiesHealth Technology Manufactures sensor technology systems | Health Technology |
Aravas, Inc.
 Aravas, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative drugs for the treatment of serious and life-threatening conditions | Health Technology |
Synexus Compass, Inc.
 Synexus Compass, Inc. Medical/Nursing ServicesHealth Services Provides medical image analysis, subject recruitment and biochemical marker services | Health Services |
Covance Biotechnology Services, Inc.
 Covance Biotechnology Services, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
The Ohio University
 The Ohio University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Plus Therapeutics, Inc.
 Plus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops radio therapeutics products | Health Technology |
Diosynth RTP, Inc.
 Diosynth RTP, Inc. BiotechnologyHealth Technology Provides current good manufacturing practices and pharmaceutical products | Health Technology |
Dominion Ventures, Inc.
 Dominion Ventures, Inc. Investment ManagersFinance Dominion Ventures invests in emerging technology companies located in the US. The firm targets companies operating in the fields of Communications, Software and Services. It acquires minority stakes & provides financing for growth stage capital requirements. It acts as lead investor with an investment size ranging from $3 to $10 million and an initial investment size of $2 - $4 million. Dominion Ventures takes a seat on the board of directors and also considers co-investments. | Finance |
id2, Inc
id2, Inc Information Technology ServicesTechnology Services Provides custom computer programming services | Technology Services |
LoopOne, Inc. | |
Pharmaco
 Pharmaco Drugstore ChainsRetail Trade Acquires, develops, and markets niche pharmaceutical products | Retail Trade |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Develops and commercializes a novel treatment for the rare disease Creatine Transporter Deficiency | Health Services |
Entvantage Diagnostics, Inc.
Entvantage Diagnostics, Inc. Medical SpecialtiesHealth Technology Develops diagnostic test kits | Health Technology |
Savara, Inc.
 Savara, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals to treat respiratory diseases | Health Technology |
Havencrest Capital Management LLC
Havencrest Capital Management LLC Investment ManagersFinance Havencrest Capital invests in lower-middle market companies located in the United States with an EBITDA of USD 3 - 15 million and enterprise value of USD 25 - 250 million. The firm focuses on a broad range of sectors and industries. It participates in add on acquisitions, buyouts, recapitalization and growth stage capital transactions. It acquires controlling and non controlling stakes. | Finance |
Lumos Pharma, Inc.
 Lumos Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and markets therapeutics for rare diseases | Health Technology |
Cytori Therapeutics, Inc.
Cytori Therapeutics, Inc. BiotechnologyHealth Technology Engages in development of treatment and devices for cell therapy | Health Technology |
Entvantage Diagnostic Associates LLC
Entvantage Diagnostic Associates LLC BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
